Health
Fresenius Lifts Forecast, Confirms Exit From Vamed Business
- Company hails final step in portfolio restructuring process
- First-quarter earnings came in ahead of analyst estimates
Fresenius headquarters near Frankfurt, Germany.
Photographer: Daniel Roland/AFP/Getty ImagesThis article is for subscribers only.
Fresenius SE raised its forecast based on strong demand for intravenous drugs and began detailing its exit from Vamed, the company’s smallest business unit.
Earnings will probably grow as much as 10% before interest and taxes in 2024, the company said in a statement Tuesday, up from a previous target of as much as 8% growth. Revenue is also expected to rise faster than previously projected, it said.